Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer

Publication date: 11 April 2016
Source:Cancer Cell, Volume 29, Issue 4
Author(s): Brett S. Carver
In this issue of Cancer Cell, Lee and colleagues (2016) define the biologic role of MYCN in promoting prostate tumorigenesis and development of a neuroendocrine phenotype. This has important implications for the clinical management of neuroendocrine prostate cancer as Aurora A kinase inhibitors promoting N-Myc destabilization progress in the clinic.

Teaser

In this issue of Cancer Cell, Lee and colleagues (2016) define the biologic role of MYCN in promoting prostate tumorigenesis and development of a neuroendocrine phenotype. This has important implications for the clinical management of neuroendocrine prostate cancer as Aurora A kinase inhibitors promoting N-Myc destabilization progress in the clinic.


from Cancer via ola Kala on Inoreader http://ift.tt/2670s1z
via IFTTT